In 2002 he became Assistant Professor of Surgery and Critical Care Medicine at the University of Toronto – Sunnybrook Health Sciences Centre. Due to his interest in research, he became the Director of Trauma Research at Sunnybrook that same year.
Dr. Rizoli’s research has focuses in two major areas, the immunological and anti-inflammatory effects of hypertonic fluids and the physiopathology and management of hemorrhagic shock in trauma.
In 2004 he completed the first randomized controlled trial (RCT) on the immunological effects of hypertonic fluids in trauma patients. He was awarded the 2006 Royal College Gold Medal in Surgery for this work. He also participated in the first clinical trial on the use of recombinant factor VIIa in bleeding trauma patients and along with colleagues from Sunnybrook has one of the largest clinical experiences with this therapy and 12 manuscripts on this topic.
Dr. Rizoli major area of interest is on clinical trials in understanding and managing early coagulopathy in trauma. He has over 100 peer-reviewed publications in medical journals including Journal of Biological Chemistry, Annals of Surgery and Lancet Infectious Diseases.
He was promoted to Associate Professor in 2007, received a CIHR/NovoNordisk New Investigator award and has recently been awarded the De Souza Research Chair in Trauma. He is the Chief of Region XII of the Committee on Trauma of the American College of Surgeons.